Comparative Pharmacology
Head-to-head clinical analysis: SITAGLIPTIN PHOSPHATE versus TRADJENTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SITAGLIPTIN PHOSPHATE versus TRADJENTA.
SITAGLIPTIN PHOSPHATE vs TRADJENTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that slows the inactivation of incretin hormones (GLP-1 and GIP), thereby increasing their levels and prolonging their action. This enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner.
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It slows the inactivation of incretin hormones GLP-1 and GIP, increasing their levels, which stimulates insulin secretion and suppresses glucagon release in a glucose-dependent manner.
100 mg orally once daily.
5 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 12.4 hours (range 8–14 hours). Clinically, supports once-daily dosing with gradual onset of DPP-4 inhibition.
Terminal elimination half-life is approximately 12.5 hours at steady state, consistent with once-daily dosing and supporting 24-hour DPP-4 inhibition.
Renal excretion: ~87% (as unchanged drug in urine); biliary/fecal: ~13% (as metabolites and unchanged drug).
Approximately 85% of the dose is excreted in feces (mostly as unchanged parent drug) and about 5% in urine (largely as metabolites). Biliary excretion accounts for the majority of fecal elimination.
Category A/B
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor